Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    This update shows a minor revision label change from v3.4.1 to v3.4.2. No substantive changes to the study details or eligibility criteria appear to have occurred.
    Difference
    0.1%
    Check dated 2026-02-12T02:23:49.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision: v3.4.1 is now displayed, replacing the previous Revision: v3.4.0.
    Difference
    0.1%
    Check dated 2026-02-04T22:34:31.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    UI updates include adding a 'Show glossary' option and modifying metadata labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and updating the revision to v3.4.0 (previously v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T21:36:16.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Date fields on the study page were updated to include new last-update timestamps (e.g., 2026-01-16 and 2027-12-31) and the 'Last Update Posted (Estimated)' label. Some older update entries were removed.
    Difference
    0.4%
    Check dated 2026-01-21T06:15:39.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T04:00:56.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Locations section now lists Connecticut and Texas as study sites, with the revision updated to v3.3.3. The HHS Vulnerability Disclosure link appears removed.
    Difference
    0.3%
    Check dated 2025-12-23T21:40:27.000Z thumbnail image

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.